Šalis: Australija
kalba: anglų
Šaltinis: Department of Health (Therapeutic Goods Administration)
furosemide, Quantity: 50 mg
Baxter Healthcare Pty Ltd
furosemide (frusemide)
Injection, solution
Excipient Ingredients: water for injections; hydrochloric acid; sodium hydroxide; sodium chloride
Intramuscular, Intravenous
5 x 5mL ampoules, 25 x 5 mL ampoules
(S4) Prescription Only Medicine
Oedema: FUROSEMIDE-BAXTER Injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. Frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. FUROSEMIDE-BAXTER Injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset is desired. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. Parenteral use should be replaced with oral frusemide as soon as practical.
Visual Identification: Clear colourless solution; Container Type: Ampoule; Container Material: Glass Type I Coloured; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Registered
2009-04-03
Furosemide- Baxter Furosemide (frusemide) Version 1.0 1 of 15 AUSTRALIAN PRODUCT INFORMATION FUROSEMIDE-BAXTER (FUROSEMIDE (FRUSEMIDE)) SOLUTION FOR INJECTION 1 NAME OF THE MEDICINE Furosemide (Frusemide). 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Furosemide (Frusemide) 20 mg/2 mL and 50 mg/5 mL solution for injection. For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Solution for injection, for Intramuscular (I.M.) or Intravenous (I.V.) use. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Oedema Furosemide-Baxter Injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. Furosemide (frusemide) is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. Furosemide-Baxter Injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide (frusemide) is indicated by the intravenous route. Parenteral use should be replaced with oral furosemide (frusemide) as soon as practical. Furosemide- Baxter Furosemide (frusemide) Version 1.0 2 of 15 4.2 DOSE AND METHOD OF ADMINISTRATION ADULTS: Parenteral therapy with Furosemide-Baxter injection should be used only in patients unable to take oral medication or in emergency situations and should be replaced with oral therapy as soon as practical. Oedema: The usual initial dose of Furosemide-Baxter is 20 to 40 mg given as a single dose, injected intramuscularly or intravenously. The intravenous dose should be given slowly (see Section 4.4 Special warnings and precautions for use). Ordinarily a prompt diuresis ensues. If neede Perskaitykite visą dokumentą